CRISPR Therapeutics AG
CRISPR Therapeutics AG logo
CRSP

CRISPR Therapeutics AG (CRSP)

$52.784.58%

Market is closed
– opens on 8 PM, 30 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$50.19
Day's Range
$53.19
$38.94
52-Week Range
$86.95
1 month return30.87%
3 month return0.84%
1 year return17.21%
5 year return18.9%

Analyst Recommendation

based on 33 analysts ratings

Buy
60%
Buy
33%
Hold
6%
Sell

Based on 33 Wall street analysts offering stock ratings for CRISPR Therapeutics AG(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 80.56%

Current

$52.78

Target

$95.3

Recommendation Trend

Based on 33 analyst

Current1M Ago3M Ago
Buy
20
9
20
Hold
11
7
11
Sell
2
2
1
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization4.1B
Book Value$24.97
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)3.76
PE Ratio13.91
PEG Ratio0.0
Wall Street Target Price95.3

Valuation

Trailing PE13.91
Forward PE23.36
Price/Book (mrq)2.01
Enterprise Value2.3B
Enterprise Value/Revenue178.1
Enterprise Value/Ebitda-3.43

Technicals

Beta1.6
50 Day MA49.95
200 Day MA60.29

Institutional Holdings

ARK Investment Management LLC

10.52%

Capital Research & Mgmt Co - Division 3

6.82%

Sumitomo Mitsui Trust Holdings Inc

5.44%

Nikko Asset Management Americas Inc

5.44%

BlackRock Inc

3.0%

T. Rowe Price Investment Management,Inc.

2.86%

Company Information

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
OrganizationCRISPR Therapeutics AG
Employees473
CEODr. Samarth Kulkarni Ph.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is CRISPR Therapeutics AG share price today?

Can Indians buy CRISPR Therapeutics AG shares?

How can I buy CRISPR Therapeutics AG shares from India?

Can Fractional shares of CRISPR Therapeutics AG be purchased?

What are the documents required to start investing in CRISPR Therapeutics AG stocks?

What are today’s High and Low prices of CRISPR Therapeutics AG?

What are today’s traded volumes of CRISPR Therapeutics AG?

What is today’s market capitalisation of CRISPR Therapeutics AG?

What is the 52 Week High and Low Range of CRISPR Therapeutics AG?

How much percentage CRISPR Therapeutics AG is down from its 52 Week High?

How much percentage CRISPR Therapeutics AG is up from its 52 Week low?

What are the historical returns of CRISPR Therapeutics AG?

Who is the Chief Executive Officer (CEO) of CRISPR Therapeutics AG?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*